As of January 31, 2023, Pfizer’s remaining share repurchase authorization is $3.3B. Current financial guidance does not anticipate any share repurchases in 2023.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PFE: